GlassScriptPhysician profile
Abigail Love Strike
NPI 1063134997
$5,244.88
in general payments reported to CMS, 2019-2025
40 companies · $1,414 in 2025
The $1,414 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,364 · 2024: $2,467 · 2025: $1,414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,162 · Consulting Fee: $875 · Education: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,161.89 |
| Consulting Fee | $875.00 |
| Education | $207.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,125.07 | 2023-2025 | Enhertu, Tagrisso, Lynparza |
| Janssen Biotech, INC. | $397.86 | 2023-2025 | Imbruvica, Darzalex, Talvey |
| Novartis Pharmaceuticals Corporation | $321.12 | 2024-2025 | |
| Glaxosmithkline, LLC. | $250.56 | 2023-2025 | Ojjaara, Zejula, Jemperli |
| Merck Sharp & Dohme LLC | $237.97 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Celgene Corporation | $231.31 | 2024-2025 | Reblozyl, Pomalyst |
| E.R. Squibb & Sons, L.L.C. | $181.45 | 2024-2025 | Opdivo, Opdualag |
| Gilead Sciences, INC. | $175.98 | 2023-2025 | Trodelvy |
| Daiichi Sankyo INC. | $170.32 | 2023-2025 | Enhertu, Injectafer |
| Incyte Corporation | $159.79 | 2024 | Monjuvi, Jakafi |
| Lilly USA, LLC | $152.70 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Pfizer INC. | $151.06 | 2024-2025 | |
| Genentech USA, INC. | $143.83 | 2024-2025 | Tecentriq, Alecensa, Polivy |
| Sobi, INC | $143.80 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $139.95 | 2024-2025 | Iclusig, Ninlaro, Alunbrig |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $131.66 | 2024-2025 | |
| Eisai INC. | $125.05 | 2024-2025 | |
| Exelixis INC. | $115.77 | 2024-2025 | Cabometyx |
| Aveo Pharmaceuticals, INC. | $92.77 | 2024-2025 | |
| Abbvie INC. | $72.34 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $67.42 | 2024-2025 | |
| Puma Biotechnology, INC. | $59.98 | 2024-2025 | |
| Tersera Therapeutics LLC | $59.47 | 2024-2025 | Zoladex |
| Stemline Therapeutics INC. | $54.64 | 2023 | Orserdu |
| Pharmaessentia USA Corporation | $53.99 | 2023-2025 | Besremi |
| Coherus Oncology, INC. | $52.04 | 2023-2024 | |
| Tempus Ai, INC | $51.74 | 2024 | |
| Emd Serono, INC. | $49.43 | 2024-2025 | |
| Mirati Therapeutics, INC. | $38.14 | 2023-2024 | Krazati |
| Deciphera Pharmaceuticals INC. | $37.27 | 2024 | Qinlock |
| Regeneron Healthcare Solutions, INC. | $35.25 | 2024 | Libtayo |
| Immunogen, INC. | $23.73 | 2023 | Elahere |
| Sumitomo Pharma America, INC. | $22.07 | 2024 | Orgovyx |
| Legend Biotech USA INC. | $19.53 | 2025 | Carvykti |
| Acrotech Biopharma INC. | $19.18 | 2024 | Beleodaq |
| Rigel Pharmaceuticals, INC. | $18.50 | 2024 | Tavalisse, Rezlidhia |
| Beigene USA, INC. | $17.28 | 2024 | Brukinsa |
| Array Biopharma INC | $15.87 | 2024 | Braftovi, Tukysa, Mektovi |
| Adaptive Biotechnologies Corporation | $15.03 | 2025 | Clonoseq |
| Servier Pharmaceuticals LLC | $13.96 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abigail Strike listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.